C

C

COURTINARD , C.

Last name: COURTINARD

First name: C.

June 3, 2024 (v1)

Journal article

Metadata-only

Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)

Courtinard, C. Barbet, V. Schiappa, R.

Background: Real-world data (RWD) can contextualize clinical trial data. We present real-world evidence thatsupplemented the single-arm DESTINY-Breast01 trial, which assessed the efficacy and safety of trastuzumabderuxtecan (T-DXd) in patients with human epidermal growth factor receptor 2-positive (HER2þ) metastatic breastcancer (mBC)...

Uploaded on: August 13, 2024
May 2018 (v1)

Journal article

Metadata-only

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients

Jacquet, E. Lardy-Cléaud, A. Pistilli, B.

BACKGROUND:For hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC), international guidelines recommend endocrine therapy as first-line treatment, except in case of 'visceral crisis'. In the latter case, chemotherapy is preferred. Few studies have compared these two strategies....

Uploaded on: December 4, 2022